An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or therapeutic h...

Full description

Bibliographic Details
Main Authors: Eva Iniguez, Nathaniel S Schocker, Krishanthi Subramaniam, Susana Portillo, Alba L Montoya, Waleed S Al-Salem, Caresse L Torres, Felipe Rodriguez, Otacilio C Moreira, Alvaro Acosta-Serrano, Katja Michael, Igor C Almeida, Rosa A Maldonado
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-10-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC5673233?pdf=render

Internet

http://europepmc.org/articles/PMC5673233?pdf=render

Similar Items